References

• American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). https://doi.org/10.1176/appi.books.9780890425787
• Brunette, M. F., Mueser, K. T., Babbin, S., Meyer-Kalos, P., Rosenheck, R., Correll, C. U., Cather, C., Robinson, D. G., Schooler, N. R., Penn, D. L., Addington, J., Estroff, S. E., Gottlieb, J., Glynn, S. M., Marcy, P., Robinson, J., & Kane, J. M. (2018). Demographic and clinical correlates of substance use disorders in first episode psychosis. Schizophrenia Research, 194, 4–12. https://doi.org/10.1016/j.schres.2017.06.039
• Coles, A. S., Knezevic, D., George, T. P., Correll, C. U., Kane, J. M., & Castle, D. (2021). Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review. Frontiers in Psychiatry, 12, 808002–808002. https://doi.org/10.3389/fpsyt.2021.808002
• Insel, T. R. (2022). Healing: Our path from mental illness to mental health. Penguin Press.
• Rognli, E. B., Heiberg, I. H., Jacobsen, B. K., Høye, A., & Bramness, J. G. (2023). Transition From Substance-Induced Psychosis to Schizophrenia Spectrum Disorder or Bipolar Disorder. The American Journal of Psychiatry, 180(6), 437-444. https://doi.org/10.1176/appi.ajp.22010076